Newer prostate Ca agent shows positive pain outcomes

Article

Recent studies of the oral androgen receptor inhibitor enzalutamide (Xtandi) evaluated the effect of costicosteroid use with the agent as well as its pain-related outcomes in patients with advanced prostate cancer.

Related Videos
Nicholas L. Kavoussi, MD, answers a question during a Zoom video interview
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Paul M. Yonover, MD, FACS, an expert on prostate cancer
Doctor typing on computer | Image Credit: © smolaw11 - stock.adobe.com
Christopher J.D. Wallis, MD, PhD, answers a question during a Zoom video interview
Related Content
© 2023 MJH Life Sciences

All rights reserved.